Alder Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Remains on Track to Complete A Robust and Integrated BLA Submission in the First Quarter of 2019
For the nine months, the company reported loss from operations of $209,160,000 compared to $235,918,000 a year ago. Net loss was $216,340,000 or $3.68 per basic and diluted share compared to $234,522,000 or $4.25 per basic and diluted share a year ago.
The company announced that it remains on track to complete a robust and integrated BLA submission in the first quarter of 2019, including chemistry, manufacturing, and controls (CMC) processes, positive results from the comparative PK study and data from eptinezumab's PROMISE 1 and PROMISE 2 pivotal Phase 3 clinical trials, as well as the long-term safety study. Continued to conduct commercial readiness activities, including expanding the Company's Medical Science Liaison team; recruiting commercial personnel; and building its reimbursement and distribution services in anticipation of eptinezumab's potential launch in the first quarter of 2020.